Follistatin-344 — Safety, Research, Risks & Legal Status

Not medical advice. Follistatin-344 is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	FS-344, myostatin inhibitor
Category	Peptide
myostatin	GDF-8 (growth differentiation factor 8); secreted protein that negatively regulates muscle growth
activins	TGF-beta superfamily cytokines involved in differentiation, growth, and immune regulation
follistatin	Natural myostatin-binding protein; produced endogenously in muscle and other tissues
US legal status	Research chemical; not FDA-approved for human use; gene therapy myostatin inhibitors are in clinical trials but not approved; sold as research chemical in US

What is Follistatin-344?

Engineered peptide that binds and inhibits myostatin (GDF-8); studied to promote muscle growth and reduce fat; popular in underground research markets. FS-344 is a truncated form of follistatin designed for higher myostatin selectivity and improved pharmacokinetics compared to full-length follistatin.

How it works

FS-344 binds myostatin (GDF-8) and related activins, blocking their interaction with serine-threonine kinase receptors ALK4 and ALK5. Myostatin is a negative regulator of muscle growth; inhibition removes the brake, allowing muscle protein synthesis to exceed degradation. Off-target effects on other activins and TGF-beta pathway members are possible.

Background & history

Myostatin inhibition research began in the late 1990s after the discovery of myostatin mutations in muscular dogs and cattle. Follistatin-derived peptides were developed as potential therapeutics for muscle wasting. FS-344 specifically emerged in the 2010s as a shorter, more selective variant. No approved pharmaceutical form exists; research chemical markets filled the gap.

What the research says

Preclinical evidence strong in animals for muscle hypertrophy; no long-term human safety or efficacy data; one small human trial halted or inconclusive; marketed muscle claims often unsubstantiated. Animal studies show robust muscle gain and fat loss; human safety profile is entirely unknown and potential off-target effects on activin and other TGF-beta superfamily members are not characterized.

Reported effects

Animal studies show significant muscle mass gain and fat reduction
Reported to inhibit myostatin-mediated muscle atrophy signals
Studied for potential use in muscle-wasting diseases and age-related loss
May preserve lean mass during caloric deficit in preclinical models
Possible effects on bone density and cardiovascular function (unknown direction in humans)

Dosing & administration (informational)

Animal studies used FS-344 at 5-25 mg/kg subcutaneously or intravenously, with significant muscle gains at 10+ mg/kg. One reported human trial used doses in the 2-5 mg range (details unclear). Underground markets cite highly variable and unvalidated dosing; bioavailability and pharmacokinetics in humans are unknown.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

No human long-term safety data; animal studies suggest tolerability but do not confirm human safety
Myostatin inhibition may cause uncontrolled muscle growth, joint stress, or organ compensation
Injection only; sterility and GMP manufacture critical; contamination risks serious (abscess, sepsis)
Doses used in underground markets are often unvalidated; no standard dosing in humans
Absolute contraindications: pregnancy, immunocompromised, active cancer (myostatin has roles in immune and tumor regulation)
Muscle growth disproportional to joint and connective tissue adaptation may cause injury

Drug & supplement interactions

Potential interaction with other myostatin inhibitors or activin-trap compounds (redundant effect)
TGF-beta pathway drugs (cancer drugs, anti-fibrotic agents) may have synergistic or antagonistic effects
Testosterone and androgens: may amplify muscle effects; combined safety unknown
Growth hormone and IGF-1: pathway overlap; combined effects uncharacterized

Who should avoid it

Pregnancy (high teratogenic risk; myostatin inhibition affects fetal muscle development)
Immunocompromised state (myostatin involved in immune regulation; risk unknown)
Active cancer or history of cancer (myostatin and activins have tumor-suppressive roles; inhibition could promote growth)
Severe joint disease or connective tissue disorder (risk of disproportionate muscle growth overwhelming joint support)
Uncontrolled diabetes or metabolic disease (TGF-beta pathway involved in glucose homeostasis)

How it is commonly combined

FS-344 is sometimes combined with anabolic steroids, growth hormone, IGF-1, or other muscle-promoting compounds in underground protocols, but no safety data exists for any combination. Synergy is assumed but untested; risk of severe adverse effects is high.

Legal & regulatory. Research chemical; not FDA-approved for human use; gene therapy myostatin inhibitors are in clinical trials but not approved; sold as research chemical in US

Quality & harm reduction

N
o
n
-
n
e
g
o
t
i
a
b
l
e
:
t
h
i
r
d
-
p
a
r
t
y
C
O
A
f
r
o
m
c
e
r
t
i
f
i
e
d
l
a
b
;
H
P
L
C
-
M
S
p
u
r
i
t
y
9
8
%
+
.
E
n
d
o
t
o
x
i
n
a
n
d
b
i
o
b
u
r
d
e
n
t
e
s
t
i
n
g
(
s
t
r
i
c
t
s
t
e
r
i
l
i
t
y
)
;
b
a
c
t
e
r
i
a
l
c
o
n
t
a
m
i
n
a
t
i
o
n
i
s
s
e
r
i
o
u
s
i
n
f
e
c
t
i
o
n
r
i
s
k
.
R
e
c
o
n
s
t
i
t
u
t
i
o
n
o
n
l
y
i
n
s
t
e
r
i
l
e
,
p
y
r
o
g
e
n
-
f
r
e
e
w
a
t
e
r
;
u
s
e
f
r
e
s
h
,
s
t
e
r
i
l
e
n
e
e
d
l
e
s
a
n
d
s
y
r
i
n
g
e
s
.
S
t
o
r
e
f
r
o
z
e
n
(
-
2
0
°
C
o
r
-
8
0
°
C
)
;
n
e
v
e
r
r
e
u
s
e
o
p
e
n
e
d
v
i
a
l
s
;
d
i
s
c
a
r
d
i
f
v
i
a
l
v
i
s
i
b
l
y
c
o
m
p
r
o
m
i
s
e
d
.

Safer, legal alternative we recommend

Progressive strength training and adequate protein plus creatine monohydrate. Proven to build muscle safely with decades of data; creatine is well-studied and inexpensive compared to research-chemical injection risk.

See our recommended pick

Lab testing & harm-reduction tools

If you are going to research a compound, verifying identity and purity is the single most protective step. Independent analytical testing and sterile-handling supplies reduce risk.

Compare testing options

Frequently asked questions

Does follistatin-344 work like the animal studies show in humans?

Unknown. One small human trial data is unclear or not published. Do NOT assume animal results translate to humans.

Will it turn me into a bodybuilder overnight?

Marketing hype. Even if it worked, uncontrolled myostatin inhibition could cause disproportionate growth, joint damage, or systemic effects.

What are the serious risks?

Injection-site infection/abscess (if not sterile), off-target myostatin effects on organs, and unknown long-term consequences of myostatin suppression.

Is it banned in sports?

Yes; myostatin inhibitors are prohibited by WADA and most sports organizations.

Could it cause cancer?

Myostatin has tumor-suppressive effects; inhibition could theoretically promote growth of dormant cancer cells. This risk is unquantified but serious.

References & further reading

Myostatin biology and muscle development: skeletal muscle and myology literature
Follistatin and activin antagonism: Endocrinology and Growth Factors journals
GDF-8 and myostatin inhibition: Development and Journal of Cellular Physiology
Muscle wasting diseases and myostatin inhibitors: rare disease and orthopedic journals
TGF-beta superfamily signaling: cell signaling and cancer biology texts